Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNK-007 with IL-2 in Relapsed/Refractory AML
NCT02781467Phase 1Terminated
- Sponsor
- Celularity Inc.
- Start
- Jul 2016
- Primary completion
- Dec 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taniraleucel in acute myeloid leukemia (AML), sponsored by Celularity Inc. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Jul 2016; status: terminated.
02
Drugs
taniraleucel
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02781467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781467.